These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 17623075)

  • 1. Relationship between the loss of neutralizing antibody binding and fusion activity of the F protein of human respiratory syncytial virus.
    Liu C; Day ND; Branigan PJ; Gutshall LL; Sarisky RT; Del Vecchio AM
    Virol J; 2007 Jul; 4():71. PubMed ID: 17623075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection and characterization of human respiratory syncytial virus escape mutants resistant to a polyclonal antiserum raised against the F protein.
    Tomé L; Frabasile S; Candia C; Pittini A; Farina N; Melero JA; Arbiza J
    Arch Virol; 2012 Jun; 157(6):1071-80. PubMed ID: 22411099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased susceptibility of human respiratory syncytial virus to neutralization by anti-fusion protein antibodies on adaptation to replication in cell culture.
    Marsh R; Connor A; Gias E; Toms GL
    J Med Virol; 2007 Jun; 79(6):829-37. PubMed ID: 17457900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the epitope for anti-human respiratory syncytial virus F protein monoclonal antibody 101F using synthetic peptides and genetic approaches.
    Wu SJ; Schmidt A; Beil EJ; Day ND; Branigan PJ; Liu C; Gutshall LL; Palomo C; Furze J; Taylor G; Melero JA; Tsui P; Del Vecchio AM; Kruszynski M
    J Gen Virol; 2007 Oct; 88(Pt 10):2719-2723. PubMed ID: 17872524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polyclonal and monoclonal antibodies specific for the six-helix bundle of the human respiratory syncytial virus fusion glycoprotein as probes of the protein post-fusion conformation.
    Palomo C; Mas V; Vázquez M; Cano O; Luque D; Terrón MC; Calder LJ; Melero JA
    Virology; 2014 Jul; 460-461():119-27. PubMed ID: 25010277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein.
    Mousa JJ; Sauer MF; Sevy AM; Finn JA; Bates JT; Alvarado G; King HG; Loerinc LB; Fong RH; Doranz BJ; Correia BE; Kalyuzhniy O; Wen X; Jardetzky TS; Schief WR; Ohi MD; Meiler J; Crowe JE
    Proc Natl Acad Sci U S A; 2016 Nov; 113(44):E6849-E6858. PubMed ID: 27791117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibody-resistant mutants selected with a respiratory syncytial virus-neutralizing human antibody fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein.
    Crowe JE; Firestone CY; Crim R; Beeler JA; Coelingh KL; Barbas CF; Burton DR; Chanock RM; Murphy BR
    Virology; 1998 Dec; 252(2):373-5. PubMed ID: 9878616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversion of somatic mutations of the respiratory syncytial virus-specific human monoclonal antibody Fab19 reveal a direct relationship between association rate and neutralizing potency.
    Bates JT; Keefer CJ; Utley TJ; Correia BE; Schief WR; Crowe JE
    J Immunol; 2013 Apr; 190(7):3732-9. PubMed ID: 23455501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody.
    Corti D; Bianchi S; Vanzetta F; Minola A; Perez L; Agatic G; Guarino B; Silacci C; Marcandalli J; Marsland BJ; Piralla A; Percivalle E; Sallusto F; Baldanti F; Lanzavecchia A
    Nature; 2013 Sep; 501(7467):439-43. PubMed ID: 23955151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of antibodies directed against human respiratory syncytial virus antigens present in two commercial preparations of human immunoglobulins with different neutralizing activities.
    Sastre P; Melero JA; García-Barreno B; Palomo C
    Vaccine; 2004 Dec; 23(4):435-43. PubMed ID: 15530691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trivalency of a Nanobody Specific for the Human Respiratory Syncytial Virus Fusion Glycoprotein Drastically Enhances Virus Neutralization and Impacts Escape Mutant Selection.
    Palomo C; Mas V; Detalle L; Depla E; Cano O; Vázquez M; Stortelers C; Melero JA
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6498-6509. PubMed ID: 27550346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of Pre-F-GCN4t, a Modified Human Respiratory Syncytial Virus Fusion Protein Stabilized in a Noncleaved Prefusion Conformation.
    Blais N; Gagné M; Hamuro Y; Rheault P; Boyer M; Steff AM; Baudoux G; Dewar V; Demers J; Ruelle JL; Martin D
    J Virol; 2017 Jul; 91(13):. PubMed ID: 28404847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus.
    Arbiza J; Taylor G; López JA; Furze J; Wyld S; Whyte P; Stott EJ; Wertz G; Sullender W; Trudel M
    J Gen Virol; 1992 Sep; 73 ( Pt 9)():2225-34. PubMed ID: 1383404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibody based in vitro potency assay as a predictor of antigenic integrity and in vivo immunogenicity of a Respiratory Syncytial Virus post-fusion F-protein based vaccine.
    Djagbare MD; Yu L; Parupudi A; Sun J; Coughlin ML; Rush BS; Sanyal G
    Vaccine; 2018 Mar; 36(12):1673-1680. PubMed ID: 29456016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein.
    Flynn JA; Durr E; Swoyer R; Cejas PJ; Horton MS; Galli JD; Cosmi SA; Espeseth AS; Bett AJ; Zhang L
    PLoS One; 2016; 11(10):e0164789. PubMed ID: 27764150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of human respiratory syncytial virus A2 and 8/60 fusion glycoprotein gene sequences and mapping of sub-group specific antibody epitopes.
    Connor AL; Bevitt DJ; Toms GL
    J Med Virol; 2001 Feb; 63(2):168-77. PubMed ID: 11170054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients.
    Collarini EJ; Lee FE; Foord O; Park M; Sperinde G; Wu H; Harriman WD; Carroll SF; Ellsworth SL; Anderson LJ; Tripp RA; Walsh EE; Keyt BA; Kauvar LM
    J Immunol; 2009 Nov; 183(10):6338-45. PubMed ID: 19841167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention.
    Magro M; Mas V; Chappell K; Vázquez M; Cano O; Luque D; Terrón MC; Melero JA; Palomo C
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3089-94. PubMed ID: 22323598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein.
    Bates JT; Keefer CJ; Slaughter JC; Kulp DW; Schief WR; Crowe JE
    Virology; 2014 Apr; 454-455():139-44. PubMed ID: 24725940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human antibody recognition of antigenic site IV on Pneumovirus fusion proteins.
    Mousa JJ; Binshtein E; Human S; Fong RH; Alvarado G; Doranz BJ; Moore ML; Ohi MD; Crowe JE
    PLoS Pathog; 2018 Feb; 14(2):e1006837. PubMed ID: 29470533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.